全文获取类型
收费全文 | 1808篇 |
免费 | 75篇 |
国内免费 | 43篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 36篇 |
妇产科学 | 49篇 |
基础医学 | 192篇 |
口腔科学 | 23篇 |
临床医学 | 325篇 |
内科学 | 316篇 |
皮肤病学 | 23篇 |
神经病学 | 204篇 |
特种医学 | 233篇 |
外科学 | 97篇 |
综合类 | 23篇 |
一般理论 | 2篇 |
预防医学 | 148篇 |
眼科学 | 24篇 |
药学 | 87篇 |
中国医学 | 1篇 |
肿瘤学 | 117篇 |
出版年
2022年 | 12篇 |
2021年 | 25篇 |
2020年 | 24篇 |
2019年 | 25篇 |
2018年 | 29篇 |
2017年 | 25篇 |
2016年 | 40篇 |
2015年 | 46篇 |
2014年 | 63篇 |
2013年 | 74篇 |
2012年 | 52篇 |
2011年 | 80篇 |
2010年 | 57篇 |
2009年 | 59篇 |
2008年 | 64篇 |
2007年 | 98篇 |
2006年 | 80篇 |
2005年 | 77篇 |
2004年 | 57篇 |
2003年 | 48篇 |
2002年 | 46篇 |
2001年 | 38篇 |
2000年 | 34篇 |
1999年 | 42篇 |
1998年 | 47篇 |
1997年 | 40篇 |
1996年 | 43篇 |
1995年 | 37篇 |
1994年 | 52篇 |
1993年 | 29篇 |
1992年 | 29篇 |
1991年 | 28篇 |
1990年 | 29篇 |
1989年 | 57篇 |
1988年 | 53篇 |
1987年 | 55篇 |
1986年 | 45篇 |
1985年 | 35篇 |
1984年 | 35篇 |
1983年 | 17篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1980年 | 11篇 |
1978年 | 6篇 |
1976年 | 9篇 |
1975年 | 8篇 |
1973年 | 4篇 |
1971年 | 4篇 |
1970年 | 5篇 |
1969年 | 5篇 |
排序方式: 共有1926条查询结果,搜索用时 0 毫秒
1.
Toshio Kushiro Hiroshige Itakura Yoshihisa Abo Hiromi Gotou Shinji Terao Deborah L Keefe 《Hypertension research》2006,29(12):997-1005
Aliskiren is a novel orally active renin inhibitor for the treatment of hypertension. This study evaluated the antihypertensive efficacy, safety and tolerability of aliskiren in Japanese patients with hypertension. Forty hundred and fifty-five Japanese men and women with a mean sitting diastolic blood pressure of 95-110 mmHg were randomized to receive once-daily double-blind treatment for 8 weeks with aliskiren 75, 150 or 300 mg or placebo. Aliskiren produced significant, dose-dependent reductions in mean sitting diastolic blood pressure (p<0.0005 vs. placebo for each dose) and mean sitting systolic blood pressure (p<0.001 vs. placebo for each dose). The placebo-corrected reductions in mean sitting systolic/diastolic blood pressure were 5.7/4.0, 5.9/4.5 and 11.2/7.5 mmHg in the aliskiren 75, 150 and 300 mg groups, respectively. After 8 weeks' treatment, 27.8%, 47.8%, 48.2% and 63.7% of patients in the placebo and aliskiren 75, 150 and 300 mg groups, respectively, achieved a successful treatment response (diastolic blood pressure <90 mmHg and/or reduced by > or =10 mmHg from baseline; p<0.005 vs. placebo for each dose). Aliskiren treatment was well tolerated, with the incidence of adverse events reported in the active treatment groups (53-55%) being similar to that in the placebo group (50%). This study, which is the first to assess the antihypertensive efficacy and safety of aliskiren in Japanese patients with hypertension, demonstrates that the once-daily oral renin inhibitor aliskiren provides significant, dose-dependent reductions in blood pressure with placebo-like tolerability. 相似文献
2.
Gahan J Pandina Robert Bilder Philip D Harvey Richard S E Keefe Michael G Aman Georges Gharabawi 《Neuropsychopharmacology》2007,62(3):226-234
BACKGROUND: Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed. METHODS: Data from two 6-week, double-blind, placebo-controlled studies (n = 228) were combined, as were three 1-year, open-label studies (n = 688). Patients with DBDs and subaverage IQ, 5 to14 years, received placebo or risperidone .02 to .06 mg/kg/day. Cognitive measures included the Continuous Performance Task (CPT) and Verbal Learning Test for Children (VLT-C). Efficacy was assessed using the Nisonger Child Behavior Rating Form (NCBRF). Adverse events were collected via spontaneous report; sedation was assessed using visual analog scale. RESULTS: Improvements on the NCBRF Conduct Problem subscale were significantly greater for risperidone- versus placebo-treated patients (-15.8 vs. -6.4, p < .0001) in short-term studies; significant reductions were observed in long-term studies (-16.3, p < .0001). No overall decline and some significant improvement in attention (CPT) and memory (VLT-C) were noted regardless of treatment in short-term studies. VLT-C improved significantly (p < .0001) for both groups, with no difference between treatment groups. Improvements in memory (VLT-C) and attention (CPT) were noted in long-term studies. Somnolence/sedation did not affect cognitive function. CONCLUSIONS: Cognitive function was not altered by risperidone in short-term studies and was maintained or improved with one year of treatment in children with DBDs and subaverage IQ, potentially representing age-appropriate gains. 相似文献
3.
M R Keefe 《ANS. Advances in nursing science》1988,10(3):70-78
Conceptually weak and unsubstantiated theories attempting to explain the origins of infant colic have led to inconsistent and ineffective approaches to the management of the infant with persistent crying. A new theoretical perspective that views excessive crying as a developmental behavioral disorder is presented. The clinical implications of this model for nurses working with families of irritable infants are discussed. 相似文献
4.
SUMMARY A case congenital dislocation of both knees and dislocation of the left hip in an infant whose mother had a chronic amniotic fluid leakage after mid-trimester amniocentesis. 相似文献
5.
高效液相色谱法测定右旋儿茶素血浆浓度及药代动力学参数 总被引:1,自引:0,他引:1
本文建立了体液中右旋儿茶素的RP-HPLC测定方法。采用C_(18)键合相硅胶为填料的固相提取柱进行样品预处理,右旋儿茶素的提取回收率为79.8%.应用二极管阵列检测器对色谱峰纯度进行鉴定。该法精密度好,方法回收率近100%,日内、日间的变异系数为2.4~5.6%,血浓69.6~1160 ng/ml范围内呈线性关系,r=0.9993。家兔静注右旋儿茶素18mg/kg,其药代动力学过程符合二室模型,分布相半衰期为0.129 h,消除相半衰期为1.19h。 相似文献
6.
Behavioral and cognitive-behavioral approaches to chronic pain are receiving increasing attention from researchers and clinicians. This article reviews and highlights recent research advances and future research directions. Assessment research reviewed includes studies examining the social context of pain, the relationship of chronic pain to depression, cognitive variables affecting pain, and comprehensive assessment measures. Treatment outcome studies reviewed are those evaluating the effects of behavioral and cognitive-behavioral treatments for chronic pain. These studies focus on comparisons of behavioral treatment with control conditions, comparisons of two behavioral treatments, and prevention of chronic pain. Future directions for assessment and treatment research are outlined. 相似文献
7.
P D Harvey M F Lenzenweger R S Keefe D L Pogge M R Serper R C Mohs 《Psychiatry research》1992,44(2):141-151
Male schizophrenic patients (n = 142) were examined with a clinical assessment of their language dysfunctions with the Scale for the Assessment of Thought, Language, and Communication (TLC). Confirmatory factor analyses were conducted to test the relative fit of several differential theoretical models of the factorial structure of thought disorders. The models examined were positive-negative thought disorder, a three-factor model based on the results of an earlier exploratory factor analysis, and a simpler verbal productivity-disconnection model that can be extracted from other exploratory analyses and empirical studies. The positive-negative thought disorder model failed to fit the data, while the three-factor model fit the data, but no better than the simpler verbal productivity-disconnection model. 相似文献
8.
石杉碱甲类似物的研究II.N-甲基吡啶酮石杉碱甲类似物的合成 总被引:4,自引:1,他引:3
石杉碱甲(1)是从中草药石杉属植物千层塔(Lycopodium serratum Thunb.)中分得的一种高效可逆的乙酰胆碱酯酶抑制剂,临床试验证实它对早老性痴呆症有显著疗效。本文报道N-甲基吡啶酮石杉碱甲类似物2和3的合成。2-甲氧基-5-甲氧羰基-11-亚甲基-5,9-甲撑环辛-7-烯并吡啶(9)在乙腈中用三甲基氯硅烷和碘化钠选择性脱保护以定量的产率得吡啶酮10,再用甲醇钠和碘甲烷甲基化得N-甲基吡啶酮11,11经碱性水解,Curtius重排和氨基的脱保护得N-甲基吡啶酮石杉碱甲类似物2。通过类似的途径从中间体2-甲氧基-5-甲氧羰基-7-甲基-11-酮-5,9-甲撑环辛-7-烯并吡啶(14)合成了类似物3。类似物2和3的乙酰胆碱酯酶抑制活性均低于天然石杉碱甲。 相似文献
9.
10.
B. J. Young R. O’Regan F. Kinsella A. Benedict-Smith M. McDermott M. Hillery L. M. T. Collum M. Hickey-Dwyer P. Mullaney J. Blake M. Hope-Ross S. Travers D. Mooney P. S. Phelan P. E. Cleary D. F. P. Larkin D. Roden P. Eustace H. N. O’Donoghue J. D. McAdoo J. G. Madden J. P. Burke M. O’Keefe R. Bowell M. O’Sullivan P. T. McLister D. J. Wilson J. Walsh 《Irish journal of medical science》1988,157(3):91-94